{"title":"Facebook and Big Pharma exploited disease “awareness” for personalized marketing","link":"https://arstechnica.com/?p=1763427","date":1620404032000,"content":"<div>\n<figure><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2018/09/GettyImages-520882250-800x533.jpg\" /><p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2018/09/GettyImages-520882250.jpg\">Enlarge</a> (credit: <a href=\"https://www.gettyimages.com/license/520882250\">Getty | YinYang</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>Pharmaceutical companies spend around $6.5 billion a year on advertising, and even though Facebook prohibits the use of “sensitive health information” in ad targeting, about $1 billion of that ad spending ends up in the companies' pockets. Big Pharma, it turns out, has found some creative ways to work within Facebook’s rules.</p>\n<p>Facebook’s ad targeting allows drug companies to zero-in on likely patients by aiming not for their conditions but for Facebook-defined interests that are adjacent to their illnesses, according to a report by <a href=\"https://themarkup.org/citizen-browser/2021/05/06/how-big-pharma-finds-sick-users-on-facebook\">The Markup</a>. The site used a custom web browser to analyze what ads Facebook served to 1,200 people and why, and it found that Big Pharma frequently used illness “awareness” as a proxy for more sensitive health information.</p>\n<p>The range of treatments advertised to potential patients ran the gamut. Novartis used “National Breast Cancer Awareness Month” to sell Facebook users on Piqray, a breast cancer pill that lists for <a href=\"https://www.fiercepharma.com/pharma/novartis-double-good-news-day-saw-fda-nod-for-blockbuster-cancer-prospect-piqray\">$15,500</a> for a 28-day supply. AstraZeneca<span> </span>ran ads for Brilinta, a <a href=\"https://www.brilinta.com/cost-assistance.html\">$405-per-month</a> blood thinner, based on whether Facebook thought a user was interested in “stroke awareness.” And GlaxoSmithKline shows ads for Trelegy, a <a href=\"https://www.gskforyou.com/gsk-pricing/trelegy/\">$600-per-month</a> inhaler, if someone was flagged by Facebook for “chronic obstructive pulmonary disease [COPD] awareness.”</p></div><p><a href=\"https://arstechnica.com/?p=1763427#p3\">Read 4 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1763427&amp;comments=1\">Comments</a></p>","author":"Tim De Chant","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"4106194b0bfadd3cfe55728122d55d76d07cd30573577c92f31a57a4ed12eb8d","category":"Tech"}